Trials / Withdrawn
WithdrawnNCT01349894
SNaP Wound Care System Over Skin Cancer Excision Sites and Split Thickness Skin Grafts (STSGs)
Post-Market Clinical Evaluation of the Spiracur SNaP™ Wound Care System for Treatment of Skin Cancer Excision Sites and Split Thickness Skin Grafts
- Status
- Withdrawn
- Phase
- —
- Study type
- Observational
- Enrollment
- 0 (actual)
- Sponsor
- Solventum US LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy of the Spiracur SNaP® Wound Care System for the treatment of skin cancer excision sites and split thickness skin grafts (STSG). The secondary purpose will be to compare the prospective patients to retrospectively treated skin cancer excision sites and STSGs to further evaluate efficacy and safety.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | SNaP® Wound Care System | Wound dressing applications using customized system. Dressing applications changes per manufacturer recommendation. |
Timeline
- Start date
- 2011-08-01
- Primary completion
- 2012-06-01
- Completion
- 2012-06-01
- First posted
- 2011-05-09
- Last updated
- 2024-10-02
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01349894. Inclusion in this directory is not an endorsement.